RACHEL SCHIFF to Estrogen Receptor Modulators
This is a "connection" page, showing publications RACHEL SCHIFF has written about Estrogen Receptor Modulators.
Connection Strength
1.009
-
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
Score: 0.233
-
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003; 5(5):228-31.
Score: 0.220
-
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
Score: 0.214
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.183
-
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20.
Score: 0.064
-
Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene. 2005 Apr 28; 24(19):3166-76.
Score: 0.062
-
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat. 2009 Sep; 117(2):243-51.
Score: 0.020
-
Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res. 2003 Sep 01; 63(17):5203-8.
Score: 0.014